Notícias e Atividades da Matinas BioPharma
Presença
Sede: Estados Unidos
Matinas BioPharma é uma empresa listada sob o símbolo MTNB (US).
Executivos
Veja o organograma con seus 6 executivos principais
Biografias mais buscadas da Matinas BioPharma
- Jerome Jabbour, President, Chief Executive Officer and Interim Chi...
- Keith Murphy, Independent Director
- Evelyn D'An, Independent Director
Recentes movimentos de executivos em Matinas BioPharma
- Robin Smith, Director, deixou a Companhia (Notícia publicada em 14 de julho de 2026).
- Keith Kucinski, Chief Financial Officer, deixou a Companhia (Notícia publicada em 26 de janeiro de 2026).
- Jerome Jabbour antes President, Chief Executive Officer and Director, agora é President, Chief Executive Officer and Interim Chief Financial Officer (Notícia publicada em 26 de janeiro de 2026).
Criar um alerta
para seguir os movimentos de executivos da Matinas BioPharma.
Biotecnologia
Matinas BioPharma possui 2.430 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).
Popular M&A news in Biotecnologia
- Tempus has announced the acquisition of Personalis (publicado em 20 de julho de 2026).
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Matinas BioPharma
- Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity
- Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
- Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
- Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
- Special Meeting of Stockholders
- Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
- Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
- Matinas BioPharma Receives NYSE Noncompliance Notice
- Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
- Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
- View more press releases Close
Redes sociais sobre Matinas BioPharma
- Matinas BioPharma na Wikipedia, Google News e Yahoo Finance
- Matinas BioPharma na LinkedIn, X (Twitter) e YouTube
